← Back to Clinical Trials
Recruiting NCT06883227

NCT06883227 Investigating Health Impacts of Exposure to Harmful Algal Blooms

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06883227
Status Recruiting
Phase
Sponsor Roskamp Institute Inc.
Condition Red Tide
Study Type OBSERVATIONAL
Enrollment 400 participants
Start Date 2024-10-14
Primary Completion 2029-10-14

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 400 participants in total. It began in 2024-10-14 with a primary completion date of 2029-10-14.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goals of this project are to study the biological effects of environmental toxins (ET), in particular aquatic toxins such as brevetoxins (PbTx) and microcystin or their metabolites. This study is designed to examine the effects of the body from harmful algae blooms (HAB) as well as possibility of an association between exposure to the marine toxin, brevetoxin (PbTx), which is released from K. brevis during the red tide bloom, and the prevalence of neurological illnesses.

Eligibility Criteria

Inclusion Criteria: 1. Subject should be able to provide written informed consent. 2. Adult aged 18 or older. 3. Resident (temporary or permanent) of one of the following five southwest Florida counties (Lee, Collier, Charlotte, Sarasota, or Manatee). 4. Any race or ethnicity. 5. Willing to return for at least a total of four study visits and participate in all required procedures for the duration of the study. Exclusion Criteria: 1. Inability to speak or write in English. 2. Any medical condition for which the study investigator believes enrollment is medically inappropriate. 3. Unwilling/unable to provide biological samples or poor venous access.

Contact & Investigator

Central Contact

Dakota Helgager Clinical Research Site Coordinator, Bachelor's

✉ redtide@roskampclinic.org

📞 9412568010

Principal Investigator

Laila Abdullah Principal Investigator, Ph.D

PRINCIPAL INVESTIGATOR

The Roskamp Institute

Frequently Asked Questions

Who can join the NCT06883227 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Red Tide. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06883227 currently recruiting?

Yes, NCT06883227 is actively recruiting participants. Contact the research team at redtide@roskampclinic.org for enrollment information.

Where is the NCT06883227 trial being conducted?

This trial is being conducted at Sarasota, United States.

Who is sponsoring the NCT06883227 clinical trial?

NCT06883227 is sponsored by Roskamp Institute Inc.. The principal investigator is Laila Abdullah Principal Investigator, Ph.D at The Roskamp Institute. The trial plans to enroll 400 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology